AtriCure gets FDA nod to try hybrid atrial fibrillation procedure
Updated 8:10 p.m., May 10, 2010. Atricure Inc. (NASDAQ: ATRC), the maker of cardiac surgical ablation systems, has received a conditional nod from the Food and Drug Administration (FDA) to evaluate the safety and efficacy of a hybrid procedure to treat patients with persistent forms of atrial fibrillation. The hybrid procedure “represents a key growth […]